Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
Gentian Kaloshi(Mother Teresa Hospital), Mentor Petrela(University of Medicine Tirana), G. Fejzo(University of Tirana), Ermir Roçi(Mother Teresa Hospital), Arben Rroji, Mehmet Hoxha(Mother Teresa Hospital), Gramoz Braçe, Teona Bushati(University of Tirana)
Cited by 13
Related Papers
Vitamin D and Its Role as a Protective Factor in Allergy
|International Scholarly Research Notices|2014|25
Platinum-based Chemotherapy in Recurrent High-grade Glioma Patients: Retrospective Study
|Medical Archives|2014|22
Case Study of a Spinal Epidural Capillary Hemangioma: A 4-Year Postoperative Follow-Up
|Global Spine Journal|2013|18
Bevacizumab Alone at 5 mg/kg in an Every-3-Week Schedule for Patients with Recurrent Glioblastomas: A Single Center Experience
|Tumori Journal|2013|13
Spinal Dissemination of Intracranial Glioblastoma in Bevacizumab Era: a Potential Bevacizumab-induced Mechanism
|Acta Informatica Medica|2014|7